Literature DB >> 9707609

Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer.

A Seth1, I Ourmanov, M J Kuroda, J E Schmitz, M W Carroll, L S Wyatt, B Moss, M A Forman, V M Hirsch, N L Letvin.   

Abstract

The utility of modified vaccinia virus Ankara (MVA) as a vector for eliciting AIDS virus-specific cytotoxic T lymphocytes (CTL) was explored in the simian immunodeficiency virus (SIV)/rhesus monkey model. After two intramuscular immunizations with recombinant MVA-SIVSM gag pol, the monkeys developed a Gag epitope-specific CTL response readily detected in peripheral blood lymphocytes by using a functional killing assay. Moreover, those immunizations also elicited a population of CD8+ T lymphocytes in the peripheral blood that bound a specific major histocompatibility complex class I/peptide tetramer. These Gag epitope-specific CD8+ T lymphocytes also were demonstrated by using both functional and tetramer-binding assays in lymph nodes of the immunized monkeys. These observations suggest that MVA may prove a useful vector for an HIV-1 vaccine. They also suggest that tetramer staining may be a useful technology for monitoring CTL generation in vaccine trials in nonhuman primates and in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707609      PMCID: PMC21470          DOI: 10.1073/pnas.95.17.10112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Studies of cloned simian immunodeficiency virus-specific T lymphocytes. gag-specific cytotoxic T lymphocytes exhibit a restricted epitope specificity.

Authors:  H Yamamoto; M D Miller; H Tsubota; D I Watkins; G P Mazzara; V Stallard; D L Panicali; A Aldovini; R A Young; N L Letvin
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

2.  [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].

Authors:  A Mayr; H Stickl; H K Müller; K Danner; H Singer
Journal:  Zentralbl Bakteriol B       Date:  1978-12

3.  E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses.

Authors:  M W Carroll; B Moss
Journal:  Biotechniques       Date:  1995-09       Impact factor: 1.993

4.  Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys.

Authors:  M D Miller; H Yamamoto; A L Hughes; D I Watkins; N L Letvin
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

5.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

6.  The MHC class I genes of the rhesus monkey. Different evolutionary histories of MHC class I and II genes in primates.

Authors:  J E Boyson; C Shufflebotham; L F Cadavid; J A Urvater; L A Knapp; A L Hughes; D I Watkins
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

7.  Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.

Authors:  V M Hirsch; T R Fuerst; G Sutter; M W Carroll; L C Yang; S Goldstein; M Piatak; W R Elkins; W G Alvord; D C Montefiori; B Moss; J D Lifson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.

Authors:  G Sutter; L S Wyatt; P L Foley; J R Bennink; B Moss
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

9.  Nonreplicating vaccinia vector efficiently expresses recombinant genes.

Authors:  G Sutter; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

10.  Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus.

Authors:  T M Allen; J Sidney; M F del Guercio; R L Glickman; G L Lensmeyer; D A Wiebe; R DeMars; C D Pauza; R P Johnson; A Sette; D I Watkins
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

View more
  38 in total

1.  A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody.

Authors:  J E Schmitz; M A Simon; M J Kuroda; M A Lifton; M W Ollert; C W Vogel; P Racz; K Tenner-Racz; B J Scallon; M Dalesandro; J Ghrayeb; E P Rieber; V G Sasseville; K A Reimann
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.

Authors:  J C Ramírez; M M Gherardi; D Rodríguez; M Esteban
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory.

Authors:  J P Christensen; P C Doherty; K C Branum; J M Riberdy
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.

Authors:  M Vaccari; A Boasso; Z-M Ma; V Cecchinato; D Venzon; M N Doster; W P Tsai; G M Shearer; D Fuchs; B K Felber; G N Pavlakis; C J Miller; G Franchini
Journal:  Mucosal Immunol       Date:  2008-09-17       Impact factor: 7.313

7.  Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules.

Authors:  J L Dzuris; J Sidney; H Horton; R Correa; D Carter; R W Chesnut; D I Watkins; A Sette
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  HIV Vaccines: Biological and Clinical Considerations.

Authors:  M. Patricia D'Souza; Mary A. Allen; Margaret I. Johnston
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

9.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

10.  Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses.

Authors:  Sampa Santra; Dan H Barouch; Birgit Korioth-Schmitz; Carol I Lord; Georgia R Krivulka; Faye Yu; Margaret H Beddall; Darci A Gorgone; Michelle A Lifton; Ayako Miura; Valerie Philippon; Kelledy Manson; Phillip D Markham; John Parrish; Marcelo J Kuroda; Jörn E Schmitz; Rebecca S Gelman; John W Shiver; David C Montefiori; Dennis Panicali; Norman L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.